Artic Fjord

CTI BioPharma, based in Seattle, WA, is dedicated to developing innovative therapies for patients with rare blood-related cancers. By delving into the scientific roots of these diseases, CTI aims to provide novel treatments that address the underlying drivers of the conditions. The company's focus on myelofibrosis has led to the approval of pacritinib in the U.S. for adults with specific platelet counts, with ongoing Phase 3 trials like PACIFICA evaluating its efficacy compared to standard therapies. CTI BioPharma's mission is centered on impacting patients' lives by advancing new medicines that offer meaningful benefits in the realm of blood cancer treatment.Generated from the website

Established in 1991, Cell Therapeutics is a publicly owned biopharmaceutical company. The company develops a variety of oncology therapy products. It offers a range of cancer therapies and treatment programs. Cell Therapeutics also conducts clinical trials for ovarian and lung cancer. It handles the storage and distribution of clinical and commercial drug supplies. The company uses the Genetic Polymer technology. Its subsidiaries include Systems Medicine and Aequus BioPharma. Systems Medicine guides the development of several oncology products. Cell Therapeutics outsource drug substance and drug product production, release testing and distribution activities to contract manufacturing organizations and service providers in the United States and Europe.

Cascadian Therapeutics Inc is a biotechnology company based in Seattle, WA, focusing on developing innovative therapies aimed at treating cancer. With a commitment to improving patient outcomes, the company employs cutting-edge technology and research to advance its therapeutic offerings. The firm is dedicated to addressing unmet medical needs in oncology, leveraging both proprietary candidates and collaborations to enhance its pipeline. Their efforts underscore a commitment to ethical practices and safeguarding patient well-being, as highlighted in their corporate policies. Generated from the website